Loading
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Previous close
$4.00
+$0.03 · +0.76%
Pre-market
$3.91
−$0.09 · -2.25%
Sep 14, 7:02 AM ET
Regular session · ET · Market data may be delayed.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Day range
Current $4.00
52-week range
Current $4.00
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
65
Bullish
Risk
52
Elevated Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Day range
Current $4.00
52-week range
Current $4.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 149.5M USD | 148.34M USD | 57.19M USD | 150.02M USD | 75.64M USD |
| Cost of goods sold | 43.18M USD | 12.3M USD | 8.22M USD | 7.38M USD | 2.65M USD |
| Gross profit | 106.32M USD | 136.04M USD | 48.97M USD | 142.63M USD | 72.99M USD |
| Research and development | 140M USD | 177.19M USD | 166.58M USD | 207.03M USD | 214.58M USD |
| Selling, general, and administrative | 39.16M USD | 71.05M USD | 52.19M USD | 58.95M USD | 63.01M USD |
| Operating expenses | 179.16M USD | 246.62M USD | 217.22M USD | 264.05M USD | 275.79M USD |
| Interest income | 3.4M USD | 9.42M USD | 9.69M USD | 1.7M USD | 680K USD |
| Interest expense | 8.51M USD | 1.12M USD | 1.43M USD | — | — |
| Depreciation and amortization | 7.17M USD | 7.54M USD | 9.65M USD | 11.87M USD | 11.26M USD |
| Operating income | −72.84M USD | −110.58M USD | −168.24M USD | −121.42M USD | −202.8M USD |
| Net income | −74.62M USD | −66.97M USD | −9.06M USD | −119.76M USD | −202.12M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
50.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.11M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM6.08M0.01%78.38B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF2.46M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO2.04M0.01%14.39B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO1.3M0.01%17.4B USD0.06%$116.76+0.36%
Fidelity Enhanced Small Cap ETFFESM1.21M0.02%6.49B USD0.28%$46.36+0.78%
iShares Micro-Cap ETFIWC847.74K0.06%1.44B USD0.60%$190.84+0.39%
ALPS Medical Breakthroughs ETFSBIO348.57K0.15%232.86M USD0.50%$63.29-0.80%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
